{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:36:21Z","timestamp":1785234981086,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clgc.2022.07.001","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T12:16:27Z","timestamp":1657541787000},"page":"595-603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7062-5001","authenticated-orcid":false,"given":"Christopher B.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam S.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.07.001_bib0001","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0002","first-page":"47","article-title":"Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial","volume":"69","author":"Pinsky","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clgc.2022.07.001_bib0003","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","article-title":"The treated natural history of high risk superficial bladder cancer: 15-year outcome","volume":"158","author":"Cookson","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0004","unstructured":"Administration USFD: Bacillus Calmette-Guerin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry, 2018."},{"key":"10.1016\/j.clgc.2022.07.001_bib0005","series-title":"Diagnosis and treatment of non-muscle invasive bladder cancer","author":"Chang","year":"2016"},{"key":"10.1016\/j.clgc.2022.07.001_bib0006","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0007","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urology.2020.05.023","article-title":"High-risk nonmuscle invasive bladder cancer: selecting the appropriate patient for timely cystectomy","volume":"147","author":"Koch","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.07.001_bib0008","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0009","series-title":"Complications of Urologic Surgery: Diagnosis, Prevention, and Management","first-page":"433","article-title":"Complications of Radical Cystectomy and Urinary Diversion","author":"Anderson","year":"2018"},{"key":"10.1016\/j.clgc.2022.07.001_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ucl.2019.09.007","article-title":"Salvage therapy using bacillus calmette-guerin derivatives or single agent chemotherapy","volume":"47","author":"Haas","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2022.07.001_bib0011","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0012","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.urology.2007.02.064","article-title":"Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion","volume":"69","author":"Lee","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.07.001_bib0013","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0014","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cncr.22826","article-title":"Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer","volume":"110","author":"Du","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.07.001_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.clgc.2022.07.001_bib0016","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0017","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.clgc.2022.07.001_bib0018","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.6004\/jnccn.2016.0150","article-title":"High-risk of adverse pathologic features in patients with clinical t1 high-grade bladder cancer undergoing radical cystectomy","volume":"14","author":"Matulewicz","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2022.07.001_bib0019","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.07.001_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ucl.2019.09.014","article-title":"Salvage therapy for non-muscle-invasive bladder cancer: novel intravesical agents","volume":"47","author":"Khaled","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2022.07.001_bib0021","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.urology.2007.09.050","article-title":"Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy","volume":"71","author":"Gallagher","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.07.001_bib0022","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on bacillus calmette-guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0023","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.juro.2010.01.025","article-title":"Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients","volume":"183","author":"Tilki","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0024","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S1078-1439(99)00020-4","article-title":"Updated concepts and treatment of carcinoma in situ","volume":"4","author":"Lamm","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: Phase II trial of pembrolizumab for patients with high-risk non-muscle invasive bladder cancer unresponsive to bacillus calmette-guerin (abstract)","volume":"37","author":"Balar","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.clgc.2022.07.001_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase i trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus calmette-guerin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0028","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.07.001_bib0029","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.juro.2016.01.087","article-title":"The timing of radical cystectomy for bacillus calmette-guerin failure: comparison of outcomes and risk factors for prognosis","volume":"195","author":"Haas","year":"2016","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.clgc.2022.07.001_bib0030","doi-asserted-by":"crossref","first-page":"436.e1","DOI":"10.1016\/j.urolonc.2021.01.004","article-title":"The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysis","volume":"39","author":"Packiam","year":"2021","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:33Z","timestamp":1761564933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1558767322001537"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}